Skip to main content

6Node page

what any key link opens

psx:substance/2m2b/claim/c91dfab6-d2e8-4a77-91b1-dbb189c52b94

claim2026-05-15recordsupported

feeds · downstream

Closure of psx:substance/2m2b/claim/c91dfab6-d2e8-4a77-91b1-dbb189c52b94: 45 upstream, 58 downstream.

psx:substance/2m2b/claim/c91dfab6-d2e8-4a77-91b1-dbb189c52b94
├─ used  src/pmid:9401766  Ethanol inhibition of N-methyl-D-aspartate-activated current in mouse hippocampal neurons: whole-cell patch-clamp analysis
  ├─ informed_by  claim/7dca280b-127e-4766-b230-e10802edd823  Claim in pharmacology — supported
  ├─ informed_by  claim/4cb1e77b-3655-47ae-a454-4af37225bd30  Claim in pharmacology — supported
  ├─ informed_by  claim/239e35e9-401c-424b-8077-ff3b9ef68af0  Claim in pharmacology — supported
  ├─ informed_by  claim/a66fa9f8-c2ab-4375-9dfd-1a281313331e  Claim in pharmacology — inconclusive  working
  ├─ informed_by  claim/59b809fa-a053-4c0b-81aa-d01af15fab0a  Claim in pharmacology — inconclusive  working
  ├─ informed_by  claim/cabfb940-44b3-4b3a-b06a-57f6e5db607c  Claim in pharmacology — supported
  ├─ informed_by  claim/62383297-1d7e-4b01-a057-cd3eabbf319c  Claim in pharmacology — supported
  ├─ informed_by  claim/37d1d179-8bdc-45cc-ac78-aaa00f03d8b9  Claim in pharmacology — supported
  ├─ informed_by  claim/6c809fb0-2e80-4d86-bccd-364c9a29194d  Claim in pharmacology — supported
    ├─ used  src/doi:10.4088/PCC.22cr03292
    ├─ used  src/doi:10.1016/j.tiv.2016.07.009  Drinking 'Vodka' or vodka - This is a question
    ├─ used  src/pmid:2467382  Ethanol inhibits NMDA-activated ion current in hippocampal neurons
    ├─ used  src/doi:10.1021/tx990078x  Biotransformation of tert-Amyl Methyl Ether and tert-Amyl Alcohol
    ├─ used  src/doi:10.1016/j.forsciint.2014.07.020  Acute intoxication due to tert-amyl alcohol - a case report
    ├─ used  src/url:7b4b65863f65011a  tert-Amyl alcohol
    ├─ used  src/url:f7ecb43a731e5328  Chemistry: Tert-Amyl alcohol
    ├─ used  src/doi:10.1016/j.forsciint.2017.10.021  Lessons learned from a case of tert-butyl glucuronide excretion in urine - 'New' psychoactive alcohols knocking on the back door?
    ├─ used  src/url:086b5df5010c341d  2m2b, a new substance with appeal to e-psychonauts: Hard to detect but ready to act. A case study
    ├─ used  src/url:71bad7c85e435ab7  2-Methyl-2-Butanol (2M2B) Ingestion Related Toxicity
    ├─ used  src/doi:10.1186/s13041-017-0325-8  Role of GABAA receptors in alcohol use disorders suggested by chronic intermittent ethanol (CIE) rodent model
    ├─ used  src/pmid:1701093  Ethanol inhibition of neuronal glutamate receptor function
    ├─ used  src/pmid:11504147  Biotransformation of MTBE, ETBE, and TAME after inhalation or ingestion in rats and humans
    ├─ used  src/doi:10.1016/j.etap.2006.07.003  Interactive effects of MTBE and TAME on liver toxicity and CYP induction in female Wistar rats
    ├─ used  src/pmid:10828258  Biotransformation and kinetics of excretion of tert-amyl-methyl ether in humans and rats after inhalation exposure
    ├─ used  src/url:0fd20b1862b68d07  2M2B - PsychonautWiki
    ├─ used  src/pmid:17323538  Alcohol withdrawal syndrome: how to predict, prevent, diagnose and treat it
    ├─ used  src/pmid:15053409  Alcohol withdrawal syndrome
    ├─ used  src/doi:10.1590/1414-431X20176889
    ├─ derived_from  gen/c884cc8f-262e-4a91-a394-dc9acc15f799  Generation — pipeline-v5
    ├─ generated_by  pub/eff6bf34-0645-4169-8ec5-58395b24be4f  Publication — backfill
      ├─ used  search/fcd73986-8613-4610-af8b-664e870082e5  Searched ClinicalTrials.gov for "2-methylbutan-2-ol tert-amyl alcohol"
      ├─ used  search/4b68d464-07f1-4391-afdc-bbd2f74f780a  Searched Crossref via verify_doi for "DOI verification for key papers"
      ├─ used  search/d66e956c-55a1-41be-8a83-0424d06f3884  Searched PubChem for "2-methylbutan-2-ol"
      ├─ used  search/4d7dafd4-d498-4eda-b853-9964166be960  Searched PubMed for "2-methylbutan-2-ol pharmacology psychoactive"
      ├─ used  search/707c6e91-4d1e-42f2-850b-47867a1f8f51  Searched PubMed for "tertiary alcohols GABA receptor anesthesia sedation"
      ├─ used  search/90ca07d8-a3c9-440b-ae6f-2976b2a72acd  Searched WebSearch for "2M2B 2-methylbutan-2-ol recreational drug pharmacology effects"
      ├─ used  search/6a5f68ab-dd0f-4dad-9350-a6b237a9b8e8  Searched PubMed for "2-methyl-2-butanol recreational misuse ethanol substitute"
      ├─ used  search/71715698-97a8-44f7-bdb8-b11aa7d7814b  Searched psychiatrist.com for "2M2B pharmacology dosing case"
      ├─ used  search/ab1cd799-36d6-4a49-b8c1-80cdee8b2447  Searched PubMed for "tert-amyl alcohol pharmacology; tert-amyl alcohol intoxication toxicology; 2m2b acute intoxication"
      ├─ used  search/e16abc37-0242-40f1-85e5-c0416fb74d7e  Searched WebSearch for "2M2B legal status scheduling controlled substance law UK US Germany"
      ├─ used  search/3af6c24e-182b-4a4a-aab0-02f8892714ff  Searched WebSearch for "amylene hydrate tert-amyl alcohol history sedative 19th century pharmacology"
      ├─ used  search/4def466d-1c1e-482a-995a-edbc2923a78c  Searched HandWiki for "tert-amyl alcohol comprehensive data"
      ├─ used  search/25c1c2e3-3de8-4bbc-b7c3-90e4c7318c31  Searched PubMed for "Lovinger NMDA receptor alcohol inhibition; ethanol GABA-A modulation; GABA cross-tolerance alcohol"
      └─ used  search/96564db2-c5dd-4ff3-b385-31a5d4d57a41  Searched Erowid for "2M2B user experience report"
├─ informed_by  section/pharmacology.full@1
  ├─ used  version/1  Revision 1
  ├─ used  claim/e3ae5830-3000-4160-8462-8b749c935493  Claim in receptor-pharmacology — supported
    ├─ derived_from  issue/notice@002688e22dc9  Issued notice
    ├─ derived_from  issue/info_card@975acdd7010f  Issued info_card
    ├─ derived_from  issue/emergency@dcd2ca271fbe  Issued emergency
    ├─ derived_from  issue/info_card@954f92e6163f  Issued info_card
    ├─ informed_by  section/receptor-pharmacology.full@1
      ├─ used  claim/b61f2145-c55b-44bc-adbf-6962489c3eda  Claim in summary — inconclusive  working
      ├─ used  claim/746dd61b-754f-4b86-b22b-1ca338dc7ab9  Claim in history — inconclusive  working
      ├─ used  claim/fef5e1cd-1f29-4c18-96e9-99c61c0e0973  Claim in safety — inconclusive  working
      ├─ used  claim/22105433-36ae-4eab-bab5-7620819713a4  Claim in safety — inconclusive  working
      ├─ used  claim/b7cfef24-7ab7-4889-a95b-31890760e848  Claim in safety — inconclusive  working
      ├─ used  claim/72f3db98-eafc-4986-a9c3-fc8e1be02c52  Claim in safety — inconclusive  working
      ├─ used  claim/0a0b14fc-cb03-4aeb-8c70-b8fb7d9e6d15  Claim in history — inconclusive  working
      ├─ used  claim/bbec84d8-8298-4f51-88bd-56d5660263f9  Claim in pharmacokinetic-detail — inconclusive  working
      ├─ used  claim/a596515e-a639-44df-91fd-611fbb247211  Claim in clinical-evidence — inconclusive  working
      ├─ used  claim/e8c8a718-5b45-4ec1-89c3-d2063a33d528  Claim in clinical-evidence — inconclusive  working
      ├─ used  claim/ac699434-579c-4b6b-b126-d7bcfde284b4  Claim in neuroscience — inconclusive  working
      ├─ used  claim/e0db9020-a9ca-452b-ad5a-7a0c42a8a295  Claim in summary — inconclusive  working
      ├─ used  claim/eabf6fb8-aa08-4439-921e-c9853ac9c594  Claim in history — inconclusive  working
      ├─ used  claim/74880632-d3a0-4998-b291-1008492a93b2  Claim in safety — supported
      ├─ used  claim/6b7feb64-d20f-479f-a824-b0e0579e418c  Claim in history — inconclusive  working
      ├─ used  claim/e99aec8c-9562-4442-895b-7c85d03457a5  Claim in summary — supported
      ├─ used  claim/dfed7f64-1b45-45fb-8a2c-9b7bf3b053b4  Claim in receptor-pharmacology — inconclusive  working
      ├─ used  claim/588a0940-2943-439c-83f1-20e33221b18d  Claim in neuroscience — inconclusive  working
      ├─ used  claim/722ede5d-19bf-4b76-a92f-dbd7e1b5f9c6  Claim in summary — supported
      ├─ used  claim/c4683fa2-fb4d-4f32-8390-79cfa5e50551  Claim in safety — inconclusive  working
      ├─ used  claim/b05c6964-1f84-425b-b470-93407132d42b  Claim in pharmacokinetic-detail — partially_supported
      ├─ used  claim/46a2e02d-80af-47ef-bb87-cb007d3acb66  Claim in pharmacokinetic-detail — inconclusive  working
      ├─ used  claim/5c314ee5-d5f7-4e66-94ab-36bc060b08ca  Claim in comparative-pharmacology — supported
      ├─ used  claim/b45bacc3-9c1e-498f-9aef-6cc17bf01351  Claim in summary — supported
      ├─ used  claim/b1e73d55-0f07-4bee-a542-870bedae95ce  Claim in safety — partially_supported
      ├─ used  claim/738a523e-3058-4319-a6bf-8561099f9e7d  Claim in safety — supported
      ├─ used  claim/bb6c138a-48aa-4c5c-a338-b561f1fb04bd  Claim in safety — supported
      ├─ used  claim/60e42056-7e37-4541-8c5a-ce7a7a514474  Claim in history — supported
      ├─ used  claim/7cef3b78-22b5-4358-b335-635bcf11b5c7  Claim in pharmacokinetic-detail — supported
      ├─ used  claim/c02a2691-fe02-4cf5-9930-0020590f5398  Claim in clinical-evidence — supported
      ├─ used  claim/ec5b8762-093e-4619-8371-4cca852e5de4  Claim in clinical-evidence — supported
      ├─ used  claim/ad20ab85-8bfc-446d-8c58-e85b841a9585  Claim in neuroscience — inconclusive  working
      ├─ used  claim/d9c9ea01-d19e-4297-97fe-bb3fc4ce61c6  Claim in history — inconclusive  working
      ├─ used  claim/31bb64f0-f51c-417b-af8c-e7151706c736  Claim in pharmacokinetic-detail — supported
      ├─ used  claim/1a58399f-c3f4-474d-89c5-0d791d0212db  Claim in safety — supported
      ├─ used  claim/55daf814-5e1b-40e1-aaad-24d5e0de6523  Claim in safety — supported
      ├─ used  claim/c1495425-0301-4613-a178-5854eeda7317  Claim in receptor-pharmacology — inconclusive  working
      ├─ used  claim/c6b5f4ac-66f2-4eb2-912a-63fcf1f3639f  Claim in neuroscience — inconclusive  working
      ├─ used  claim/8d278dec-fc7f-4c46-bcee-ed09e4250444  Claim in receptor-pharmacology — supported
      ├─ used  claim/0f28e41c-8a0e-465d-bb32-bc5952ff7e4f  Claim in pharmacokinetic-detail — inconclusive  working
      ├─ used  claim/e2b7cbe2-9995-4cf4-b165-a216a6cbaa1b  Claim in pharmacokinetic-detail — supported
      ├─ used  claim/66bb917e-7870-4492-9af1-9979871a0255  Claim in safety — supported
      ├─ used  claim/6ef9f920-6c8b-40c1-a429-afcbbef3feab  Claim in safety — supported
      ├─ used  claim/ef271c53-edc3-4a62-baf4-f0481870e652  Claim in pharmacokinetic-detail — supported
      ├─ used  claim/724c3547-0f4e-442f-99e7-11b6dab88737  Claim in pharmacokinetic-detail — supported
      ├─ used  claim/0415e7ad-4c0a-4820-9f07-6fd9dd446bd7  Claim in neuroscience — supported
      ├─ used  claim/31c17241-455c-4bb7-9f4f-4c95673163e4  Claim in safety — supported
      ├─ used  claim/cc4b366a-9768-4f65-8011-1db242136ba2  Claim in neuroscience — supported
      ├─ used  claim/37debdd3-1ec5-4d7b-9a7f-c89ef0b0191e  Claim in safety — supported
      └─ used  claim/9eb13527-a8f0-4826-b005-cff96552faa8  Claim in safety — supported
… closure truncated at 200 nodes

indented by distance from this node, not by parentage

1Provenance card

the boundary, as counts

Sources

208 with DOI

0 strong · 12 moderate · 8 weak

Compilations

12026-05-15T19:41:14.012Z

pipeline-v5 · prompt hash not recorded — run predates 2026-09

Decisions

29last ruled 2026-06-04

0 awaiting a ruling

Issued documents

42026-10-19T20:29:30.002Z

notice · info card · emergency

Searches

143 with no results

queries and counts on the build

Claims checked

6136 supported

36 supported · 25 not

Correspondence

0received

consent field ships in Phase 4

Edges

198

derivations recorded for this entity

Complete over 20 sources, 1 compilation, and 29 decisions.Not here: the private journal (never).Working material — drafts, discards, unsupported claims — is listed below and readable on the working page.Cite: psychedex.org/substances/2m2b/archive

2Build

one panel per compilation run

generation run 2026-05-15

62 min completedmodel pipeline-v5plan not recordedrun/0b255672…

Selection

results seen61
selected by the model36
consumed as sources20

Verification

claims checked61
supported34
partially supported2
not supported0
inconclusive25
  • record
  • seen / partial
  • working

The model's own caveats

  • sparse_evidence
  • structural_inference
  • future_opportunity

Reproduce

inputs
20 source keys (listed under Sources)
plan
not recorded — template version, prompt hash and git SHA are written from 2026-09 onward
model
pipeline-v5
streams
none — agent transcripts are persisted from 2026-09 onward
14 searches — query, source, results, what was kept and why
14 searches for this run
#sourcequeryseenkeptrationale
1PubMedLovinger NMDA receptor alcohol inhibition; ethanol GABA-A modulation; GABA cross-tolerance alcohol104Class-level pharmacological evidence for NMDA antagonism and GABA-A modulation applicable to 2M2B
2WebSearchamylene hydrate tert-amyl alcohol history sedative 19th century pharmacology104Historical context and basic toxicological data
3Crossref via verify_doiDOI verification for key papers61Verification of citation accuracy
4PubMed · absence2-methylbutan-2-ol pharmacology psychoactive0——
5HandWikitert-amyl alcohol comprehensive data14Key physical and toxicological data not in PubMed
6PubMed2-methyl-2-butanol recreational misuse ethanol substitute11Primary clinical reference for 2M2B recreational use
7PubMed · absencetertiary alcohols GABA receptor anesthesia sedation0——
8psychiatrist.com2M2B pharmacology dosing case13Full article detail not available via PubMed abstract
9WebSearch2M2B 2-methylbutan-2-ol recreational drug pharmacology effects104Primary sources for clinical and user-report data
10Erowid2M2B user experience report13User-report data for subjective effects characterization
11PubMedtert-amyl alcohol pharmacology; tert-amyl alcohol intoxication toxicology; 2m2b acute intoxication108All directly relevant: cytotoxicity, forensic detection, case reports, biotransformation
12PubChem2-methylbutan-2-ol11Primary chemical identity verification
13WebSearch2M2B legal status scheduling controlled substance law UK US Germany103Legal status data for major jurisdictions
14ClinicalTrials.gov · absence2-methylbutan-2-ol tert-amyl alcohol0——
61 claims by section — every cited sentence, checked against its source
safety16 · 11 ok
  • Two published cases document respiratory failure requiring emergency intubation: a 28-year-old male in deep coma with acute respiratory failure (blood tert-amyl alcohol 83 μg/mL), and a 41-year-old female requiring field intubation and ICU admission.partially supported

    A case of 28 year-old male found in deep coma complicated with acute respiratory failure due to recreational intoxication with tert-amyl alcohol. Blood level 83 ug/mL by GC-MS. j.forsciint.2014.07.020

  • Claim in safety — inconclusiveinconclusiveworking →

  • In HEK293 cells, 2M2B cytotoxicity (MTT assay) is comparable to ethanol and significantly lower than 3-methyl-1-butanol (an isoamyl alcohol isomer)supported

    The MTT test indicated that the toxicity of 2M2B was comparable to that of ethanol, but it was much lower than that observed after 3-methyl-1-butanol. j.tiv.2016.07.009

  • At higher concentrations, 2M2B induces cell cycle arrest and autophagy in retinoblastoma cells via the PI3K/Akt pathway, with dose-dependent toxicity to normal cells.supported

    2M2B leads to HXO-RB44 cell death but is cytotoxic to normal cells at higher concentrations. MBT induced cell cycle arrest, apoptosis and autophagy through the PI3K/Akt pathway. 1414-431x20176889

  • Rat studies of the structurally related compound TAME (which is metabolized to 2M2B) showed elevated liver toxicity markers and significant CYP enzyme induction (up to 260-fold CYP2B1 induction), suggesting hepatic stress with chronic exposuresupported

    Hepatomegaly and CYP2E1 induction (2-fold) and CYP2B1 induction (up to 260-fold) observed in TAME-treated rats. j.etap.2006.07.003

  • Claim in safety — inconclusiveinconclusiveworking →

  • Claim in safety — inconclusiveinconclusiveworking →

  • Cross-tolerance with other GABAergic drugs — including benzodiazepines, barbiturates, neurosteroids, and other alcohols — is supported by extensive class-level evidence from ethanol researchsupported

    Tolerance to ethanol results in cross-tolerance to other GABAergic drugs including benzodiazepines, anesthetics, and neurosteroids. s13041-017-0325-8

  • Withdrawal from 2M2B is expected to produce a syndrome clinically indistinguishable from alcohol or benzodiazepine withdrawal: tremor, anxiety, insomnia, diaphoresis, seizures, and potentially delirium tremenssupported

    Describes spectrum of alcohol withdrawal from minor symptoms to delirium tremens. Benzodiazepines are the best-assessed drugs for preventing severe alcohol withdrawal including seizures. pmid:17323538

  • Withdrawal from 2M2B is expected to produce a syndrome clinically indistinguishable from alcohol or benzodiazepine withdrawal: tremor, anxiety, insomnia, diaphoresis, seizures, and potentially delirium tremenssupported

    Spectrum of alcohol withdrawal from insomnia and tremulousness to seizures and delirium tremens. Pharmacologic treatment involves medications cross-tolerant with alcohol. Benzodiazepines are agents of choice. pmid:15053409

  • Co-administration with opioids, benzodiazepines, barbiturates, ethanol, or GHB produces synergistic respiratory depression through convergent mechanisms: additive GABA-A potentiation and, in the case of ethanol, additive NMDA antagonismsupported

    GABAergic inhibitory transmission is involved in the acute and chronic effects of ethanol on the brain and behavior. Tolerance to ethanol results in cross-tolerance to other GABAergic drugs including benzodiazepines, anesthetics, and neurosteroids. s13041-017-0325-8

  • Claim in safety — inconclusiveinconclusiveworking →

  • Published case reports note that 2M2B users are frequently polysubstance-dependent individuals who combine the compound with other depressants, making these interactions clinically relevant rather than theoretical.supported

    Popularity of TAA growing in Europe among alcohol/drug addicted people. Main reasons: self-healing of addiction, low price, and difficulty of detection in screening tests. j.forsciint.2014.07.020

  • Claim in safety — inconclusiveinconclusiveworking →

  • CYP2E1 inhibitors — including disulfiram and certain industrial solvents — may impair the cytochrome P450-dependent clearance of 2M2B, prolonging and intensifying intoxicationsupported

    CYP2E1 induction (2-fold) and CYP2B1 induction (up to 260-fold) observed in TAME-treated rats. j.etap.2006.07.003

  • Respiratory insufficiency or compromised airway — 2M2B causes dose-dependent respiratory depression. Published cases document respiratory failure requiring intubation. Pre-existing respiratory compromise reduces the margin to fatal respiratory arrest.supported

    A case of 28 year-old male found in deep coma complicated with acute respiratory failure due to recreational intoxication with tert-amyl alcohol. j.forsciint.2014.07.020

pharmacology10 · 8 ok
  • Chronic intermittent exposure in rodent models produces persistent subunit composition changes lasting months.supported

    Chronic exposure leads to persistent changes in GABA-A receptor subunit composition lasting at least 120 days in rats. s13041-017-0325-8

  • Alcohols inhibit NMDA-activated ion current in hippocampal neurons in a concentration-dependent manner, and the potency for NMDA inhibition correlates linearly with intoxicating potency across a series of aliphatic alcoholssupported

    Inhibition increased in a concentration-dependent manner (5-50 mM). The potency for inhibition of NMDA-activated current by several alcohols is linearly related to their intoxicating potency. pmid:2467382

  • The inhibition is non-competitive and voltage-independent; ethanol neither acts as a channel pore blocker nor competes with glutamate or glycine at their binding sitessupported

    Ethanol inhibited NMDA-activated current in a voltage-independent manner. Ethanol decreased the maximal response to NMDA and glycine without affecting their EC50 values. Results consistent with ethanol inhibiting NMDA receptor function by a non-competitive mechanism. pmid:9401766

  • NMDA receptor selectivity over other ionotropic glutamate receptor subtypes (AMPA, kainate) is established for the alcohol class.supported

    Ethanol is less effective in inhibiting ion current produced by non-NMDA glutamate receptors. pmid:1701093

  • Claim in pharmacology — inconclusiveinconclusiveworking →

  • Claim in pharmacology — inconclusiveinconclusiveworking →

  • CYP2E1 and CYP2B1 are the principal isoforms responsible for oxidationsupported

    CYP2E1 induction (2-fold) and CYP2B1 induction (up to 260-fold) observed in TAME-treated rats. j.etap.2006.07.003

  • The major metabolites — 2-methyl-2,3-butanediol (free and glucuronide-conjugated), 2-hydroxy-2-methylbutyric acid, and 3-hydroxy-3-methylbutyric acid — are non-toxic relative to acetaldehyde, which accounts for the reduced hangover reported by users.supported

    Major urinary metabolites: glucuronidated 2-methyl-2,3-butanediol, 2-hydroxy-2-methylbutyric acid, 3-hydroxy-3-methylbutyric acid. These reactions are mediated by cytochrome P450-dependent oxidations. tx990078x

  • Urinary metabolite elimination half-lives range from 6 to 40 hours in humans, substantially slower than in rats (under 6 hours)supported

    Metabolite excretion in humans was slower than rats; elimination half-lives between 6 and 40 h in humans for TAA metabolites. pmid:10828258

  • Urinary metabolite elimination half-lives range from 6 to 40 hours in humans, substantially slower than in rats (under 6 hours)supported

    Human metabolite elimination half-lives between 6 and 40 h. pmid:11504147

pharmacokinetic-detail9 · 6 ok
  • Claim in pharmacokinetic-detail — inconclusiveinconclusiveworking →

  • The principal CYP isoforms implicated are CYP2E1 and CYP2B1, based on rat induction studies of the structurally related compound TAME, which produced 2-fold CYP2E1 induction and up to 260-fold CYP2B1 inductionsupported

    CYP2E1 induction (2-fold) and CYP2B1 induction (up to 260-fold) observed in TAME-treated rats. j.etap.2006.07.003

  • The primary metabolites identified in human urine following TAME exposure are:partially supported

    Biotransformation of tert-amyl alcohol studied in rats after gavage. Major urinary metabolites: glucuronidated 2-methyl-2,3-butanediol, 2-hydroxy-2-methylbutyric acid, 3-hydroxy-3-methylbutyric acid. tx990078x

  • Claim in pharmacokinetic-detail — inconclusiveinconclusiveworking →

  • Urinary metabolite elimination half-lives in humans range from 6 to 40 hours — markedly slower than the under-6-hour half-lives observed in ratssupported

    Metabolite excretion in humans was slower than rats; elimination half-lives between 6 and 40 h in humans for TAA metabolites. pmid:10828258

  • Urinary metabolite elimination half-lives in humans range from 6 to 40 hours — markedly slower than the under-6-hour half-lives observed in ratssupported

    Human metabolite elimination half-lives between 6 and 40 h. pmid:11504147

  • Claim in pharmacokinetic-detail — inconclusiveinconclusiveworking →

  • 2M2B is not detected by standard immunoassay urine drug screens or breath alcohol analyzers used in emergency, occupational, and forensic settingssupported

    Main reasons: self-healing of addiction, low price, and difficulty of detection in screening tests. j.forsciint.2014.07.020

  • The glucuronide metabolite of tert-amyl alcohol may produce false-positive results on immunological ethyl glucuronide (EtG) screening, creating forensic interpretive complications.supported

    False-positive immunological EtG screenings by excretion of different alcohol glucuronides. j.forsciint.2017.10.021

history6 · 1 ok
  • Claim in history — inconclusiveinconclusiveworking →

  • Claim in history — inconclusiveinconclusiveworking →

  • Claim in history — inconclusiveinconclusiveworking →

  • Claim in history — inconclusiveinconclusiveworking →

  • Claim in history — inconclusiveinconclusiveworking →

  • The first published case report of acute 2M2B intoxication appeared in 2014, documenting a 28-year-old male found in deep coma with acute respiratory failure and a blood tert-amyl alcohol concentration of 83 μg/mLsupported

    A case of 28 year-old male found in deep coma complicated with acute respiratory failure due to recreational intoxication with tert-amyl alcohol. Blood level 83 ug/mL by GC-MS. j.forsciint.2014.07.020

neuroscience6 · 2 ok
  • These adaptations produce a state of latent neural hyperexcitability that becomes manifest upon abrupt cessation — the neurobiological basis of withdrawal seizures, anxiety, tremor, and delirium tremens in the GABAergic withdrawal syndrome.supported

    Describes spectrum of alcohol withdrawal from minor symptoms to delirium tremens. Benzodiazepines are the best-assessed drugs for preventing severe alcohol withdrawal including seizures. pmid:17323538

  • These adaptations produce a state of latent neural hyperexcitability that becomes manifest upon abrupt cessation — the neurobiological basis of withdrawal seizures, anxiety, tremor, and delirium tremens in the GABAergic withdrawal syndrome.supported

    Spectrum of alcohol withdrawal from insomnia and tremulousness to seizures and delirium tremens. pmid:15053409

  • Claim in neuroscience — inconclusiveinconclusiveworking →

  • Claim in neuroscience — inconclusiveinconclusiveworking →

  • Claim in neuroscience — inconclusiveinconclusiveworking →

  • Claim in neuroscience — inconclusiveinconclusiveworking →

summary5 · 3 ok
  • Claim in summary — inconclusiveinconclusiveworking →

  • Claim in summary — inconclusiveinconclusiveworking →

  • As a tertiary alcohol, 2M2B potentiates GABA-A receptor-mediated chloride conductance and inhibits NMDA receptor-activated currents — the same dual mechanism responsible for ethanol intoxication, but at substantially lower absolute dosessupported

    The potency for inhibition of NMDA-activated current by several alcohols is linearly related to their intoxicating potency. pmid:2467382

  • Unlike ethanol, 2M2B cannot be oxidized by alcohol dehydrogenase, eliminating acetaldehyde production and the associated hangover syndrome; metabolism proceeds instead through cytochrome P450 oxidation.supported

    These reactions are mediated by cytochrome P450-dependent oxidations. tx990078x

  • Respiratory depression is the primary life-threatening acute toxicity, with published cases requiring emergency intubationsupported

    A case of 28 year-old male found in deep coma complicated with acute respiratory failure due to recreational intoxication with tert-amyl alcohol. j.forsciint.2014.07.020

clinical-evidence4 · 2 ok
  • This represents the earliest published case report of acute 2M2B intoxication and documented the growing European abuse trend in the context of addiction self-medication and toxicological detection evasion.supported

    Popularity of TAA growing in Europe among alcohol/drug addicted people. Main reasons: self-healing of addiction, low price, and difficulty of detection in screening tests. j.forsciint.2014.07.020

  • Claim in clinical-evidence — inconclusiveinconclusiveworking →

  • Claim in clinical-evidence — inconclusiveinconclusiveworking →

  • The uniformly negative standard toxicology screen underscores the need for GC-MS confirmation when 2M2B ingestion is suspected.supported

    Blood level 83 ug/mL by GC-MS... difficulty of detection in screening tests. j.forsciint.2014.07.020

receptor-pharmacology4 · 2 ok
  • Claim in receptor-pharmacology — inconclusiveinconclusiveworking →

  • Alcohols selectively inhibit NMDA-activated currents while sparing kainate- and quisqualate-activated currents in hippocampal neurons, with potency correlating to intoxicating dose across the alcohol seriessupported

    Intoxicating concentrations of ethanol inhibit NMDA-activated ion current... Ethanol is less effective in inhibiting ion current produced by non-NMDA glutamate receptors. pmid:1701093

  • The mechanism is non-competitive, voltage-independent, and does not involve pore blockade or competition at glutamate or glycine binding sites.supported

    Ethanol inhibited NMDA-activated current in a voltage-independent manner. Ethanol decreased the maximal response to NMDA and glycine without affecting their EC50 values. Results consistent with ethanol inhibiting NMDA receptor function by a non-competitive mechanism. pmid:9401766

  • Claim in receptor-pharmacology — inconclusiveinconclusiveworking →

comparative-pharmacology1 · 1 ok
  • The absence of acetaldehyde production — a direct consequence of the tertiary alcohol structure blocking ADH-mediated oxidation — accounts for both the reported lack of hangover and the absence of disulfiram-type aversive reactions.supported

    Biotransformation of tert-amyl alcohol studied in rats after gavage. Major urinary metabolites: glucuronidated 2-methyl-2,3-butanediol, 2-hydroxy-2-methylbutyric acid, 3-hydroxy-3-methylbutyric acid. These reactions are mediated by cytochrome P450-dependent oxidations. tx990078x

3Sources

20 consumed · sorted by year · feeds = sections resting on it

Sources
yearsourcetierstatusfeeds
20242-Methyl-2-Butanol (2M2B) Ingestion Related ToxicityDiaz E, Bhatty DB et al.url:71bad7c85e435ab7weakconsumedcited only
20242M2B - PsychonautWikiPsychonautWiki contributorsurl:0fd20b1862b68d07weakconsumedcited only
2024Chemistry: Tert-Amyl alcoholHandWiki contributorsurl:f7ecb43a731e5328weakconsumedcited only
2024tert-Amyl alcoholWikipedia contributorsurl:7b4b65863f65011aweakconsumedcited only
20222m2b, a new substance with appeal to e-psychonauts: Hard to detect but ready to act. A case studyUnknown (Psychiatry Research Case Reports, 2022)url:086b5df5010c341dweakconsumedcited only
2022Recreational 2-Methyl-2-Butanol Use: An Emerging Wave of Misuse of an Ethanol Substitute on the Horizon?Syed AN, Leo RJ · The Primary Care Companion for CNS Disordersdoi:10.4088/pcc.22cr03292weakconsumedcited only
20182-Methyl 2-butanol suppresses human retinoblastoma cells through cell cycle arrest and autophagyLi X, Zhu X, Xu C, Wu J · Brazilian Journal of Medical and Biological Researchdoi:10.1590/1414-431x20176889moderateconsumedcited only
2017Lessons learned from a case of tert-butyl glucuronide excretion in urine - 'New' psychoactive alcohols knocking on the back door?Arndt T, Buschmann HC, Schulz K, Stemmerich K · Forensic Science Internationaldoi:10.1016/j.forsciint.2017.10.021weakconsumed2 sections
2017Role of GABAA receptors in alcohol use disorders suggested by chronic intermittent ethanol (CIE) rodent modelOlsen RW, Liang J · Molecular Braindoi:10.1186/s13041-017-0325-8moderateconsumed4 sections
2016Drinking 'Vodka' or vodka - This is a questionRusiecka I, Gagalo I, Anand JS, Schetz D, Waldman W · Toxicology in Vitrodoi:10.1016/j.tiv.2016.07.009moderateconsumed3 sections
2014Acute intoxication due to tert-amyl alcohol - a case reportAnand JS, Gieron J, Lechowicz W, Schetz D, Kala M, Waldman W · Forensic Science Internationaldoi:10.1016/j.forsciint.2014.07.020weakconsumed6 sections
2007Alcohol withdrawal syndrome: how to predict, prevent, diagnose and treat itPrescrire International editorial staff · Prescrire Internationalpmid:17323538moderateconsumed2 sections
2007Interactive effects of MTBE and TAME on liver toxicity and CYP induction in female Wistar ratsElovaara E, Stockmann-Juvala H, Mikkola J, Gelboin HV · Environmental Toxicology and Pharmacologydoi:10.1016/j.etap.2006.07.003moderateconsumed3 sections
2004Alcohol withdrawal syndromeBayard M, McIntyre J, Hill KR, Woodside J · American Family Physicianpmid:15053409moderateconsumed2 sections
2001Biotransformation of MTBE, ETBE, and TAME after inhalation or ingestion in rats and humansDekant W, Bernauer U, Rosner E, Amberg A · Research Report (Health Effects Institute)pmid:11504147moderateconsumed2 sections
2000Biotransformation and kinetics of excretion of tert-amyl-methyl ether in humans and rats after inhalation exposureAmberg A, Rosner E, Dekant W · Toxicological Sciencespmid:10828258moderateconsumed2 sections
1999Biotransformation of tert-Amyl Methyl Ether and tert-Amyl AlcoholAmberg A, Bernauer U, Scheutzow D, Dekant W · Chemical Research in Toxicologydoi:10.1021/tx990078xmoderateconsumed5 sections
1997Ethanol inhibition of N-methyl-D-aspartate-activated current in mouse hippocampal neurons: whole-cell patch-clamp analysisPeoples RW, White G, Lovinger DM, Weight FF · British Journal of Pharmacologypmid:9401766moderateconsumed2 sections
1990Ethanol inhibition of neuronal glutamate receptor functionLovinger DM, White G, Weight FF · Annals of Medicinepmid:1701093moderateconsumed2 sections
1989Ethanol inhibits NMDA-activated ion current in hippocampal neuronsLovinger DM, White G, Weight FF · Sciencepmid:2467382moderateconsumed4 sections
—Searched ClinicalTrials.gov for "2-methylbutan-2-ol tert-amyl alcohol" — no resultsabsenceno results—
—Searched PubMed for "2-methylbutan-2-ol pharmacology psychoactive" — no resultsabsenceno results—
—Searched PubMed for "tertiary alcohols GABA receptor anesthesia sedation" — no resultsabsenceno results—

4Docket

one filing per activity — decisions, correspondence, reports

  1. 0012026-05-15revisionRevision 1

    Initial LLM generation (v5 pipeline, wiki, prose phase)

    psx:substance/2m2b/version/1
  2. 0022026-06-04proposal27 value proposals approved together

    one review action inferred from a shared reviewer and instant — the graph records one activity per proposal

    27 items in this filing

    • contraindication · other
    • contraindication · hepatic
    • contraindication · neurological
    • contraindication · psychiatric
    • contraindication · pregnancy_breastfeeding
    • dose_tier · threshold
    • dose_tier · light
    • dose_tier · common
    • dose_tier · strong
    • dose_tier · heavy
    • timeline · oral · onset
    • timeline · oral · come_up
    • timeline · oral · peak
    • timeline · oral · resolution
    • timeline · oral · afterglow
    • toxicity
    • dependence · full
    • withdrawal
    • tolerance
    • dosage · oral
    • duration · oral · onset
    • duration · oral · come_up
    • duration · oral · peak
    • duration · oral · offset
    • duration · oral · total
    • duration · oral · aftereffects
    psx:substance/2m2b/proposal/contraindication/55ab53bd-409f-4f49-8591-5a91b2df7d44
  3. 0032026-06-04publicationPublication — backfill

5Issued documents

what the notice, info card and emergency page said, by hash

Issued documents
documentcontent hashissuedfrom versionsuperseded
info_card954f92e6163f7adf5868c78b…2026-10-19 20:29Revision 1current
emergencydcd2ca271fbe095dc7fb6211…2026-09-04 04:27Revision 1current
info_card975acdd7010f206b97b47e67…2026-09-04 04:27Revision 1superseded2026-10-19
notice002688e22dc92cf5d96ebcdf…2026-09-04 04:27Revision 1current